ProsperityEHR Onboards Charis Counseling, Advancing Connected Behavioral Health Ecosystems
Wisconsin-based practice with over 20 clinicians adopts modern EHR platform to enhance patient care, reduce administrative burdens, and drive clinical...
COVID-19
ISM® Appoints Susan Spence as Chair of ISM Manufacturing PMI® Business Survey Committee
Timothy R. Fiore CPSM, C.P.M., Honored for Distinguished Service; Spence Named as His Successor TEMPE, Ariz., May 13, 2025 /PRNewswire/...
Shineco’s Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic...
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA FilingDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical...
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL...
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”)...
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been...
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3,...
Digital Wound Management Devices Market to Reach USD 3,594.49 million By 2032, Growing At An 5.03% CAGR – Credence Research
PUNE, India, May 5, 2025 /PRNewswire/ -- The global Digital Wound Management Devices Market was valued at USD 2,415.89 million...
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®,...
Hologic Announces Financial Results for Second Quarter of Fiscal 2025
– Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS...
Seegene’s CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in JulyWith a fully...
Manufacturing PMI® at 48.7%; April 2025 Manufacturing ISM® Report On Business®
New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Growing; Customers' Inventories Too Low...
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in...
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
SmartTRAK Unveils Addressable Market Projection Report for Skin Substitutes to Help Companies Navigate LCD Policy Changes
IRVINE, Calif., April 30, 2025 /PRNewswire/ -- SmartTRAK, the leading provider of real-time market intelligence and strategic insights for the...
AI Companion Pallie AI Raises $2 Million to Reduce Loneliness and Improve Wellbeing
Round led by True Ventures; Company Founded by PhD Researchers SAN FRANCISCO, April 30, 2025 /PRNewswire/ -- Pallie AI, a technology...